Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.39 |
| ▸ | CASR known ✓ | P41180 | 1/20 | 0.37 |
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.37 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL503105 | 1.00 | GFPT1 (0.44) | GFPT1GGT1ALOX15BLMPMP22 | |
| SCHEMBL1527344 | 0.98 | GFPT1 (0.46) | GFPT1GGT1ALOX15BLMPMP22 | |
| SCHEMBL574087 | 0.98 | GFPT1 (0.46) | GFPT1GGT1ALOX15BLMPMP22 | |
| SCHEMBL393844 | 0.98 | GFPT1 (0.46) | GFPT1GGT1ALOX15BLMPMP22 | |
| Adipic Acid SCHEMBL8055763 | 0.87 | BHMT (0.45) | GFPT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL19371887 | 0.82 | GFPT1 (0.32) | GFPT1 | |
| SCHEMBL22122969 | 0.82 | GFPT1 (0.32) | GFPT1 | |
| SCHEMBL27644223 | 0.82 | SLC7A5 (0.42) | GGT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL27644228 | 0.82 | SLC7A5 (0.42) | GGT1ALOX15BLMPMP22KMT2A | |
| SCHEMBL5812527 | 0.80 | SLC7A5 (0.41) | GGT1ALOX15BLMPMP22KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354573-A | Method for large-scale production of alpha, alpha-terpyridine | 河南阿尔法医药科技有限公司 | 2021-09-07 | — | — | CN | claimed |
| EP-4401758-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Takeda Pharmaceutical Company Limited (JP) | 2024-07-24 | — | — | EP | disclosed |
| CN-114288253-B | Stable intranasal carbetocin formulations | 阿卡蒂亚药品公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-112969450-B | Carbetocin pharmaceutical product and process for preparing the same | 阿卡蒂亚药品公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023042096-A1 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | WO | disclosed |
| CN-113354573-B | Method for large-scale production of alpha, alpha-terpyridine | 河南阿尔法医药科技有限公司 | 2023-03-17 | — | — | CN | disclosed |
| US-11207373-B2 | Agitation process for preparing a carbetocin drug product | LEVO THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-113354573-A | Method for large-scale production of alpha, alpha-terpyridine | 河南阿尔法医药科技有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20200093885-A1 | CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING THE SAME | ACADIA PHARMACEUTICALS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-9655902-B2 | Guanidine derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2948445-B1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| CN-104936952-A | Guanidine derivatives for the treatment of hepatitis c | BRISTOL MYERS SQUIBB CO | 2015-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207373-B2 | Agitation process for preparing a carbetocin drug product | PRKD2, PRKD1, DCTD | PTGS1 4722/4885CASR 4869/4885GRIN2D 1353/4885 |
| US-20200093885-A1 | CARBETOCIN DRUG PRODUCT AND PROCESS FOR PREPARING THE SAME | PRKD2, DCTD, NCAPD2 | PTGS1 4664/4885CASR 4877/4885GRIN2D 2267/4885 |
| US-20150320757-A1 | GUANIDINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | GMPS, GANC, GUCY1A1 | PTGS1 483/4885CASR 4855/4885GRIN2D 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.